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Abstract 
Review on PTK6, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: BRK 
HGNC (Hugo): PTK6 
Location: 20q13.33 
Note: Chromosome 2 in Mouse. 
DNA/RNA 
Description 
The PTK6 gene contains 8948 bp comprising 8 
coding exons. PTK6 belongs to a small family of 
intracellular tyrosine kinases with conserved 
functional domain homology that is related to, but 
distinct from, the SRC family of kinases (Lee et al., 
1998); reviewed in (Serfas and Tyner, 2003; Brauer 
and Tyner, 2010). Members of the PTK6 family are 
defined by a highly conserved intron-exon structure 
that is distinct from other major intracellular tyrosine 
kinase families; other family members include FRK 
(FYN-related kinase, also known as Rak) and SRMS 
(SRC-related kinase lacking C-terminal regulatory 
tyrosine and N-terminal myristoylation sites). The 
PTK6 and SRMS genes are tightly linked on human 
chromosome 20q13.3 (Kohmura et al., 1994; Llor et 
al., 1999; Serfas and Tyner, 2003). 
Transcription 
Alternative splicing gives rise to an RNA encoding a 
small protein containing the amino terminus, the 
SH3 domain, and a unique carboxyl terminus 





Size: 451 amino acids; ~ 52 KDa. 
PTK6 contains SH3 and SH2 protein-protein 
interaction domains, an SH1 kinase domain, and a 
regulatory carboxy terminus.  
Phosphorylation of residue Y342 is required for full 
activation of kinase activity and activity is 
negatively regulated by tyrosine phosphorylation of 
its carboxy-terminal tyrosine residue, Y-447 (Qiu 
and Miller, 2002; Qiu and Miller, 2004; Qiu et al., 
2005). 
Isoform 2 (also known as ALT-PTK6, delta m5) 
Size: 134 aa; ~15 KDa. 
ALT-PTK6 is the product of an alternatively-spliced 
RNA that encodes a truncated protein due to a 
premature stop codon; alternative splicing deletes 
exon 2 and causes in a frameshift.  
The N-terminus and SH3 domain of ALT-PTK6 are 
identical to the full-length protein, but it has a unique 
C-terminus lacking the SH2 and SH1 domains and is 
thus catalytically inactive (Mitchell et al., 1994; 
Brauer et al., 2011). 











Two additional PTK6 sequences, CRA_a (GenBank: 
EAW75262.1) and CRA_b (GenBank: 
EAW75263.1) that would encode larger ~59 kDa 
proteins have been identified by Celera Genomics, 
but these isoforms have not been characterized and 
their biological significance is not known. 
Expression 
Normal Epithelium 
PTK6 was first identified in cultured human 
melanocytes (Lee et al., 1993), breast tumor cells 
(Mitchell et al., 1994), and mouse small intestine 
(Siyanova et al., 1994). It is primarily an epithelial 
kinase that is first detectable in the differentiating 
granular layer of the skin during late embryogenesis 
of the mouse at E15.5 (Vasioukhin et al., 1995). In 
adults, PTK6 is predominantly expressed in the 
epithelial cells of the gastrointestinal tract (Siyanova 
et al., 1994; Llor et al., 1999), and skin (Vasioukhin 
et al., 1995; Wang et al., 2005). In regenerating 
tissues, such as the small intestine, colon, and skin, 
PTK6 expression is largely restricted to epithelial 
cells that are exiting the cell cycle and undergoing 
terminal differentiation, which are located on the 
villi in the small intestine, surface epithelium in the 
colon (Haegebarth et al., 2006), and the suprabasal 
layer of the skin (Vasioukhin et al., 1995; Wang et 
al., 2005) as well as in the oral mucosa (Petro et al., 
2004). PTK6 is also expressed in the nuclei of 
normal epithelium of the prostate (Derry et al., 
2003), and mammary gland (Peng et al., 2014). 
Although it is largely restricted to epithelia, PTK6 
expression was also reported in activated normal T-
cells (Kasprzycka et al., 2006). 
Cancer 
PTK6 is overexpressed in a large majority of human 
breast tumors and in most breast cancer cell lines 
(Barker et al., 1997; Harvey and Crompton, 2003; 
Ostrander et al., 2007). PTK6 expression is also 
induced in prostate tumors and cell lines (Zheng et 
al., 2012); relocalization of PTK6 from the nucleus 
to cytoplasm was reported in prostate cancer cells 
(Derry et al., 2003). In breast cancer cells, PTK6 
expression has been shown to be mediated by 
hypoxia via multiple mechanisms; PTK6 protein is 
stabilized by HSP90 (Kang et al., 2012) and is 
transcriptionally upregulated by HIF-1α and HIF-2α 
(Regan Anderson et al., 2013), additionally PTK6 
protein can be upregulated in a post-translational 
manner in response to hypoxia (Pires et al., 2014). 
PTK6 has been identified as a transcriptional target 
of CREB, and its expression is upregulated by 
p90RSK2 phosphorylation of CREB (Jin et al., 
2013). PTK6 expression is modestly upregulated in 
primary colon tumors (Llor et al., 1999), and 
downregulated in metastatic colon cancer (Chen et 
al., 1999). In squamous cell carcinoma, PTK6 
expression is reduced with increasing malignancy 
(Petro et al., 2004; Wang et al., 2005). 
Function 
PTK6 is an intracellular protein tyrosine kinase that 
has distinct context-dependent functions in different 
normal and cancerous tissues based on its 
intracellular localization and kinase activity. Studies 
in breast and ovarian cancer cell lines find that PTK6 
interacts with growth factor receptors EGFR 
(Kamalati et al., 2000) and ERBB2 (Ostrander et al., 
2007; Xiang et al., 2008) to propagate growth factor-
mediated signaling. PTK6 binds and phosphorylates 
IGF-1R (Fan et al., 2013) and promotes anchorage 
independent growth via interactions with IRS-4 and 
IGF1R (Qiu et al., 2005; Irie et al., 2010). PTK6 has 
also been shown to mediate Met receptor signaling, 
although a direct interaction has not been 
demonstrated (Locatelli et al., 2012). PTK6 
stabilizes EGFR expression by phosphorylating 
ARAP1 (Arf-GAP, Rho-GAP, ankyrin repeat, and 
pleckstrin homology domain-containing protein 1) 
(Kang et al., 2010); interaction with EGFR mediates 
PTK6 phosphorylation of paxillin (Chen et al., 2004) 
and p190RhoGAP (Shen et al., 2008) in breast 
cancer cells as well as AKT in breast (Zhang et al., 
2005) and prostate (Zheng et al., 2010) cancer cell 
lines to promote proliferation, invasion, and 
migration. PTK6 has also been shown to promote 
breast cancer cell migration via phosphorylation of 
KAP3A (Lukong and Richard, 2008) and Dok1 
(Miah et al., 2014). Membrane-targeted active PTK6 
in prostate cancer cell lines phosphorylates pro-
oncogenic substrates BCAR1 (Zheng et al., 2012) 
and FAK (Zheng et al., 2013a). PTK6 
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phosphorylates and activates Signal Transducers and 
Activators of Transcription STAT3 (Liu et al., 2006) 
and STAT5a (Weaver and Silva, 2007) as well as the 
related scaffolding protein STAP2 (Mitchell et al., 
2000). β-catenin has also been identified as a PTK6 
substrate; when targeted to the cell membrane PTK6 
can activate β-catenin, while nuclear PTK6 
negatively regulates β-catenin transcriptional 
activity in a kinase-independent manner (Palka-
Hamblin et al., 2010). PTK6 phosphorylation of the 
nuclear RNA-splicing factors SAM68 (Derry et al., 
2000) and related SLM1 and SLM2 proteins 
(Haegebarth et al., 2004), as well as PSF (Lukong et 
al., 2009) inhibits their RNA-binding activity to 
promote differentiation and cell cycle arrest. PTK6 
is a substrate of the PTP1B phosphatase (Fan et al., 
2013). 
PTK6 promotes epithelial differentiation of 
enterocytes in the small intestine (Haegebarth et al., 
2006) and keratinocytes in skin (Vasioukhin and 
Tyner, 1997; Wang et al., 2005). In cultured human 
keratinocytes, addition of calcium promotes 
differentiation, which is accompanied by increased 
PTK6 expression and activation, and elevated levels 
of the epidermal differentiation markers (Vasioukhin 
and Tyner, 1997) dependent on PTK6 kinase activity 
(Wang et al., 2005). Disruption of the Ptk6 gene led 
to impaired intestinal differentiation and increased 
intestinal proliferation in mice (Haegebarth et al., 
2006). When ectopically expressed, PTK6 sensitized 
non-transformed Rat1a fibroblasts to apoptosis 
(Haegebarth et al., 2005). Induction of PTK6 in 
intestinal crypts following total body γ-irradiation 
enhanced apoptosis in the murine intestinal 
epithelium, including in intestinal crypts, where it 
promotes DNA damage-induced apoptosis 
(Haegebarth et al., 2009). In human colon cancer cell 
lines and in murine colon tissue, PTK6 negatively 
regulates β-catenin transcriptional activity (Palka-
Hamblin et al., 2010). PTK6 has a tumor-promoting 
role in the colon as disruption of the Ptk6 gene 
impaired carcinogen-induced tumorigenesis in mice 
(Gierut et al., 2011) and PTK6 promotes survival of 
colon cancer cell lines following DNA damaging 
treatments including γ-irradiation and 
chemotherapeutic drugs via STAT3 activation 
(Gierut et al., 2012). 
Targeting PTK6 to plasma membrane enhanced 
proliferation, survival, migration and anchorage-
independent growth in HEK293 cells, while nuclear 
targeting inhibited the invasive phenotype (Kim and 
Lee, 2009). Targeting active PTK6 to the plasma 
membrane in SYF (deficient for SRC, YES, and 
FYN) mouse embryonic fibroblasts was sufficient to 
transform these cells (Zheng et al., 2013a). In 
prostate cancer cells, targeting PTK6 to the nucleus 
inhibits proliferation while cytoplasmic PTK6 
promotes proliferation (Brauer et al., 2010). 
Overexpression of membrane-targeted active PTK6 
in prostate cancer cells drives epithelial-
mesenchymal transition (Zheng et al., 2012) and 
anchorage-independent survival (Zheng et al., 
2013a) as well as in vivo xenograft metastasis 
(Zheng et al., 2013b). Recently, PTK6 was detected 
in nuclei of normal mammary gland epithelium 
(Peng et al., 2014), and overexpression of PTK6 
promotes oncogenic signaling and invasive 
phenotypes in breast cancer cells (Harvey and 
Crompton, 2003; Xiang et al., 2008; Irie et al., 2010). 
In human prostate and breast cancers, PTK6 is 
activated at the plasma membrane (Zheng et al., 
2013b; Peng et al., 2014). 
Mutations 
Somatic 
A few PTK6 mutations have been reported in human 
cancers. A frameshift mutation resulting in the 
deletion of 58 amino acid residues (W78fsX58) has 
been identified in a human bladder cancer cell line 
and NSCLC cell line (Ruhe et al., 2007). Two point 
mutations have been reported in a small number of 
melanoma cases; W210X within the tyrosine kinase 
domain and a -7 intronic C>T mutation within a 
splice site (Prickett et al., 2009). Additional 




PTK6 is overexpressed in most human breast tumors 
and breast cancer cell lines (Barker et al., 1997; Born 
et al., 2005; Ostrander et al., 2007; Irie et al., 2010). 
Irie and colleagues detected increased levels of 
PTK6 mRNA expression in HER2/ERBB2, luminal 
A and luminal B subtypes of breast cancer and found 
that high PTK6 expression correlated with reduced 
recurrence-free survival (Irie et al., 2010). PTK6 
protein expression has prognostic significance in 
breast cancer (Born et al., 2005; Aubele et al., 2009), 
and active PTK6 protein was detected in human 
breast tumors but not normal human mammary gland 
(Peng et al., 2014). Overexpression of PTK6 
promotes mammary gland cancer tumorigenesis in 
mouse models (Lofgren et al., 2011; Peng et al., 
2013). PTK6 sustains EGFR signaling via 
transactivation as well as by inhibition of EGFR 
degradation (Kang et al., 2010; Li et al., 2012). The 
correlation between PTK6 and ERBB2 
overexpression in invasive human ductal breast 
carcinomas (Born et al., 2005; Aubele et al., 2007; 
Ostrander et al., 2007; Xiang et al., 2008) raises the 
possibility that targeting PTK6 along with ERBB 
receptors might offer a therapeutic advantage 
(Harvey and Crompton, 2004; Ostrander et al., 
2010). In response to HGF stimulation, PTK6 
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mediates Met signaling to promote breast cancer cell 
migration (Castro and Lange, 2010). PTK6 binds 
with IGF-1R to mediate IGF-1 signaling promoting 
anchorage-independent growth (Irie et al., 2010). 
PTK6 expression is upregulated by hypoxia and 
promotes hypoxia-mediated breast cancer 
progression (Aubele et al., 2009; Kang et al., 2012; 
Pires et al., 2014). 
Prostate cancer 
Elevated expression and relocalization of PTK6 have 
been reported in prostate cancer. Analysis of 
Oncomine microarray data showed that PTK6 
mRNAs levels are higher in metastatic prostate 
tumors, and patients with high PTK6 have reduced 
survival (Zheng et al., 2013b). Knockdown of PTK6 
in the human PC3 prostate tumor cell line inhibited 
xenograft tumor growth (Zheng et al., 2013). In 
normal prostate epithelium, PTK6 expression is 
nuclear and expression relocalizes to the cytoplasm 
and membrane in poorly-differentiated prostate 
tumors (Derry et al., 2003). Targeting PTK6 to the 
nucleus in prostate cancer cells arrests their growth 
while cytoplasmic PTK6 promotes proliferation 
(Brauer et al., 2010). In the cytoplasm, PTK6 may 
phosphorylate AKT on tyrosine residues to promote 
activation and downstream signaling (Zheng et al., 
2010). Targeting active PTK6 to the plasma 
membrane in prostate cancer cells drives epithelial-
mesenchymal transition via activation of BCAR1 
(Zheng et al., 2012) and anchorage-independent 
survival via activation of FAK (Zheng et al., 2013a). 
RSK-mediated expression of PTK6 may contribute 
to metastasis of prostate cancer cells (Yu et al., 
2014). 
Colon cancer 
PTK6 expression is mildly up-regulated in primary 
colon tumors (Llor et al., 1999), and down-regulated 
in metastatic colon cancer (Chen et al., 1999). 
Disruption of Ptk6 impairs carcinogen induced 
tumorigenesis in mice, suggesting a tumor-
promoting role for the kinase in the colon as well 
(Gierut et al., 2011). In human colon cancer cell 
lines, PTK6 promotes cell survival following DNA 
damaging treatments including γ-irradiation and 
chemotherapeutic drugs via STAT3 activation 
(Gierut et al., 2012). 
Other cancers 
PTK6 has been implicated in several different types 
of human cancer, with distinct context-specific 
functions. As in breast and prostate cancers, PTK6 
has pro-oncogenic roles in some other cancers. The 
Ptk6 gene is amplified and PTK6 protein is 
overexpressed in  and may promote the development 
and growth of ovarian tumors (Schmandt et al., 
2006). PTK6 signaling via IGF1R in ovarian cancer 
promotes cell growth and is inhibitted by PTP1B 
(Fan et al., 2013). PTK6 is also overexpressed in 
head and neck cancer, where it may play a role in 
HNSCC development and progression (Lin et al., 
2004). High PTK6 expression is associated with 
poor prognosis and metastasis in nasopharyngeal 
carcinoma (Liu et al., 2013a). PTK6 expression is 
increased in non-small cell lung carcinoma (Fan et 
al., 2011) and is associated with poor prognosis 
(Zhao et al., 2013); PTK6 has been identified as a 
potential therapeutic target in NSCLC (Yauch et al., 
2005; Li et al., 2010). It has also been demonstrated 
that knockdown of PTK6 reduces migration and 
invasion of pancreatic cancer cells (Ono et al., 2014). 
Constitutive expression of PTK6 has been reported 
in cutaneous T-cell lymphomas as well as in other 
transformed T- and B-cell populations (Kasprzycka 
et al., 2006).  
In some cases, PTK6 may have tumor suppressor 
functions. It is down-regulated in human esophageal 
squamous cell carcinomas (ESCC); knockdown of 
PTK6 in human ESCC cells enhanced xenograft 
tumor growth (Ma et al., 2012). Low PTK6 
expression correlates with poor prognosis in patients 
with laryngeal squamous cell carcinoma (Liu et al., 
2013b). PTK6 expression is reduced with increasing 
malignancy in squamous cell carcinomas of the skin 
(Wang et al., 2005) and oral mucosa (Petro et al., 
2004). 
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